Time to incorporate time in cost-effectiveness analysis

被引:16
|
作者
van de Wetering, Gijs [1 ]
Woertman, Willem H. [1 ]
Adang, Eddy M. [1 ]
机构
[1] Radboud Univ Nijmegen, Dept Epidemiol Biostat & HTA, Med Ctr, NL-6500 HB Nijmegen, Netherlands
来源
EUROPEAN JOURNAL OF HEALTH ECONOMICS | 2012年 / 13卷 / 03期
关键词
Time; Economic evaluation; Short run; Cost-effectiveness; DECISION-MAKING; ECONOMIC-EVALUATION; CARE;
D O I
10.1007/s10198-011-0374-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
Cost-effectiveness analysis as a means to evaluate medical innovations has become well accepted in the UK and several other Western countries. An important assumption underlying this method is that costs and effects are constant over time. In reality, however, and especially in the short run, variations in costs and effects are likely to occur. These variations can lead to considerable deviations from the outcome of a conventional economic evaluation, which in turn may lead to serious implementation problems at a local level. Taking time into account explicitly in economic evaluations in health care may enhance their utility for both societal and local decision making, and may ultimately smooth the adoption of new and basically cost-effective health care technologies.
引用
收藏
页码:223 / 226
页数:4
相关论文
共 50 条
  • [41] Cost-effectiveness analysis and capital costs
    Karlsson, G
    Johannesson, M
    SOCIAL SCIENCE & MEDICINE, 1998, 46 (09) : 1183 - 1191
  • [42] Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy for Ovarian Cancer Prevention A Cost-effectiveness Analysis
    Matsuo, Koji
    Chen, Ling
    Matsuzaki, Shinya
    Mandelbaum, Rachel S.
    Ciesielski, Katharine M.
    Silva, Jack P.
    Klar, Maximilian
    Roman, Lynda D.
    Accordino, Melissa K.
    Melamed, Alexander
    Elkin, Elena
    Hershman, Dawn L.
    Wright, Jason D.
    ANNALS OF SURGERY, 2023, 277 (05) : E1116 - E1123
  • [43] Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
    Johannesson, M
    Meltzer, D
    OConor, RM
    MEDICAL DECISION MAKING, 1997, 17 (04) : 382 - 389
  • [44] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    G. B. Gomez
    D. W. Dowdy
    M. L. Bastos
    A. Zwerling
    S. Sweeney
    N. Foster
    A. Trajman
    M. A. Islam
    S. Kapiga
    E. Sinanovic
    G. M. Knight
    R. G. White
    W. A. Wells
    F. G. Cobelens
    A. Vassall
    BMC Infectious Diseases, 16
  • [45] An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
    Franklin, Matthew
    Lomas, James
    Walker, Simon
    Young, Tracey
    PHARMACOECONOMICS, 2019, 37 (05) : 631 - 643
  • [46] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    Gomez, G. B.
    Dowdy, D. W.
    Bastos, M. L.
    Zwerling, A.
    Sweeney, S.
    Foster, N.
    Trajman, A.
    Islam, M. A.
    Kapiga, S.
    Sinanovic, E.
    Knight, G. M.
    White, R. G.
    Wells, W. A.
    Cobelens, F. G.
    Vassall, A.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [47] Cost-effectiveness of therapies for melanoma
    Johnston, Karissa M.
    McPherson, Emily
    Osenenko, Katherine
    Vergidis, Joanna
    Levy, Adrian R.
    Peacock, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (02) : 229 - 242
  • [48] Biosimilar medicines and cost-effectiveness
    Simoens, Steven
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 29 - 36
  • [49] Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden
    Neovius, Kristian
    Buesch, Katharina
    Sandstrom, Kristina
    Neovius, Martin
    ACTA PAEDIATRICA, 2011, 100 (10) : 1306 - 1314
  • [50] Missing data in trial-based cost-effectiveness analysis: the current state of play
    Noble, Sian Marie
    Hollingworth, William
    Tilling, Kate
    HEALTH ECONOMICS, 2012, 21 (02) : 187 - 200